LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...

Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Donald Trump has a lot of thoughts. Most of them don't make any sense, and the sentences themselves are often barely ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...